Coline Bichlmaier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Coline Bichlmaier has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Roman Lang
Leibniz Institute for Food Systems Biology, Technical University of Munich, 85354 Freising, Germany
4 shared publications - Antonella Di Pizio
Leibniz Institute for Food Systems Biology at the Technical University of Munich Freising Germany
2 shared publications - Maik Behrens
Leibniz Institute for Food Systems Biology at the Technical University of Munich, 85354 Freising, Germany
2 shared publications - Thomas Skurk
ZIEL – Institute for Food & Health, Technische Universität München, Freising, Deutschland
2 shared publications - Alexandra Steuer
TUM Graduate School, TUM School of Life Sciences Weihenstephan, Technical University of Munich, Alte Akademie 8, 85354 Freising, Germany; Leibniz Institute for Food Systems Biology at the Technical University of Munich, Lise-Meitner-Str. 34, 85354 Freising, Germany
1 shared publication Angelika Graßl
Leibniz Institute for Food Systems Biology at the Technical University of Munich, Lise-Meitner-Str. 34, 85354 Freising, Germany
1 shared publication
Latest Publications
- Open Access
- 25 March 2025
- Published by Qeios Ltd
Review of: "Disruption, Diversity, and Due Diligence: Charting the Course for Coffee's Future—Key Takeaways from the International Coffee Convention 2024 (ICC2024)"
The review article about "DISRUPTION, DIVERSITY, AND DUE DILIGENCE: CHARTING THE COURSE FOR COFFEE'S FUTURE—KEY TAKEAWAYS FROM THE INTERNATIONAL COFFEE CONVENTION 2024 (ICC2024)" is clear and effectively summarizes the key insights from the event. It...
- 25 March 2025
- Published by Qeios Ltd
Open AccessReview of: "Disruption, Diversity, and Due Diligence: Charting the Course for Coffee's Future—Key Takeaways from the International Coffee Convention 2024 (ICC2024)"
The review article about "DISRUPTION, DIVERSITY, AND DUE DILIGENCE: CHARTING THE COURSE FOR COFFEE'S FUTURE—KEY TAKEAWAYS FROM THE INTERNATIONAL COFFEE CONVENTION 2024 (ICC2024)" is clear and effectively summarizes the key insights from the event. It...
- Open Access
- 6 July 2024
- Published by MDPI AG in Proceedings
- Vol. 109 (1) , 22
Mozambioside Degrades during Coffee Roasting into Newly Identified Pyrolysis Compounds with Lower Activation Thresholds for Bitter Receptors
As a global commodity with profound economic and social impact, coffee’s uniqueness is rooted in its distinctive flavor profile, characterized by roasty odors and a bitter taste. Mozambioside, a diterpene glucoside predominantly found in Arabica coffee, has emerged as a potent activator of human bitter receptors TAS2R43 and TAS2R46, exhibiting a bitterness threshold ten times lower than caffeine. The roasting process degrades mozambioside into new compounds. The roasting products were purified from model pyrolysis using liquid chromatographic techniques and their structures were elucidated and characterized by time-of-flight mass spectrometry (MS) and nuclear magnetic resonance spectroscopy. Mozambioside and its roasting products were quantified by targeted UHPLC-MS/MS in coffee powders and brews. Bitter receptor activation was investigated in HEK 293T-Gα16gust44 cells in terms of activation threshold and dose-response. Receptor activation thresholds of the major roasting products 11-O-β-D-glucosyl-(S)-16-desoxy-17-oxocafestol-2-on, 11-O-β-D-glucosyl-15,16-dehydrocafestol-2-on, 11-O-β-D-glucosyl-(R)-16-desoxy-17-oxocafestol-2-on, and bengalensol were lower than those of mozambioside. Molecular Modelling clarified the protein–molecule interaction. The compounds were formed during coffee roasting, reaching their maximum concentration in the final roasting grade. Quantitative analyses revealed that the degradation products were quantitatively extracted from the powder into the brew. During roasting, mozambioside undergoes degradation, giving rise to new compounds with a lower activation threshold for bitter receptors, putatively contributing to the bitterness of Arabica coffee brews. Advanced analytical techniques provide insights into the intricate chemistry underlying coffee’s unique flavor profile.
- 6 July 2024
- Published by MDPI AG in Proceedings
- Vol. 109 (1) , 22
Open AccessMozambioside Degrades during Coffee Roasting into Newly Identified Pyrolysis Compounds with Lower Activation Thresholds for Bitter Receptors
As a global commodity with profound economic and social impact, coffee’s uniqueness is rooted in its distinctive flavor profile, characterized by roasty odors and a bitter taste. Mozambioside, a diterpene glucoside predominantly found in Arabica coffee, has emerged as a potent activator of human bitter receptors TAS2R43 and TAS2R46, exhibiting a bitterness threshold ten times lower than caffeine. The roasting process degrades mozambioside into new compounds. The roasting products were purified from model pyrolysis using liquid chromatographic techniques and their structures were elucidated and characterized by time-of-flight mass spectrometry (MS) and nuclear magnetic resonance spectroscopy. Mozambioside and its roasting products were quantified by targeted UHPLC-MS/MS in coffee powders and brews. Bitter receptor activation was investigated in HEK 293T-Gα16gust44 cells in terms of activation threshold and dose-response. Receptor activation thresholds of the major roasting products 11-O-β-D-glucosyl-(S)-16-desoxy-17-oxocafestol-2-on, 11-O-β-D-glucosyl-15,16-dehydrocafestol-2-on, 11-O-β-D-glucosyl-(R)-16-desoxy-17-oxocafestol-2-on, and bengalensol were lower than those of mozambioside. Molecular Modelling clarified the protein–molecule interaction. The compounds were formed during coffee roasting, reaching their maximum concentration in the final roasting grade. Quantitative analyses revealed that the degradation products were quantitatively extracted from the powder into the brew. During roasting, mozambioside undergoes degradation, giving rise to new compounds with a lower activation threshold for bitter receptors, putatively contributing to the bitterness of Arabica coffee brews. Advanced analytical techniques provide insights into the intricate chemistry underlying coffee’s unique flavor profile.
- Open Access
- 1 March 2024
- Published by Elsevier in Food Chemistry
- Vol. 446, 138884
Identification of mozambioside roasting products and their bitter taste receptor activation
- 1 March 2024
- Published by Elsevier in Food Chemistry
- Vol. 446, 138884
Open AccessIdentification of mozambioside roasting products and their bitter taste receptor activation
- Open Access
Validation of N-Methylpyridinium as a Feasible Biomarker for Roasted Coffee Intake
Health-related nutritional human studies rely on the validity of dietary data provided by study participants. Reliable biomarkers for food intake help objectify data collected by food frequency questionnaires. They facilitate the monitoring of compliance with the study requirements, e.g., abstinence from food, help clean biased data, and remove non-compliant individuals. Biomarker candidates are often revealed by sophisticated metabolomics analyses of body fluids, e.g., urine or plasma, collected from case and control study populations. However, validation for using a biomarker candidate in real-life scenarios is seldomly executed. Coffee is a food item of high interest because of the abundance of bioactive compounds and the regularity of life-time consumption by a large part of the population. Coffee has been found to positively impact cardiovascular risk, type 2 diabetes, and cognitive decline. Coffee and its health implications, therefore, are of high interest. A suitable dietary biomarker for coffee consumption is desirable for the clear classification of study participants as coffee drinkers or non-coffee drinkers to enable correlation of physiological response to dietary habits, e.g., coffee consumption. Here, we propose the roast coffee compound N-methylpyridinium (NMP) as a promising biomarker of pragmatic use to distinguish a coffee drinker from a non-coffee drinker. NMP is an easily accessible analytical target from the plasma and urine matrix that can help determine precedent exposure to roasted coffee products. We review the published information on the coffee compound N-methylpyridinium in foods, coffee, and plasma/urine after coffee consumption, and evaluate the data in the context of the proposed food biomarker criteria “plausibility”, “time- and dose–response”, “robustness”, “reliability”, “stability”, “analytical performance”, and “reproducibility”. An additional data set is acquired to fill the gaps in the literature. In summary, we conclude that the abundance of NMP can serve as a reliable analytical tool to verify recent consumption of roasted coffee. The use of NMP appears limited to being qualitative, as NMP abundance in coffee and human biosamples is affected by several parameters, e.g., the roasting conditions and the volume and time of coffee consumed.
Open AccessValidation of N-Methylpyridinium as a Feasible Biomarker for Roasted Coffee Intake
Health-related nutritional human studies rely on the validity of dietary data provided by study participants. Reliable biomarkers for food intake help objectify data collected by food frequency questionnaires. They facilitate the monitoring of compliance with the study requirements, e.g., abstinence from food, help clean biased data, and remove non-compliant individuals. Biomarker candidates are often revealed by sophisticated metabolomics analyses of body fluids, e.g., urine or plasma, collected from case and control study populations. However, validation for using a biomarker candidate in real-life scenarios is seldomly executed. Coffee is a food item of high interest because of the abundance of bioactive compounds and the regularity of life-time consumption by a large part of the population. Coffee has been found to positively impact cardiovascular risk, type 2 diabetes, and cognitive decline. Coffee and its health implications, therefore, are of high interest. A suitable dietary biomarker for coffee consumption is desirable for the clear classification of study participants as coffee drinkers or non-coffee drinkers to enable correlation of physiological response to dietary habits, e.g., coffee consumption. Here, we propose the roast coffee compound N-methylpyridinium (NMP) as a promising biomarker of pragmatic use to distinguish a coffee drinker from a non-coffee drinker. NMP is an easily accessible analytical target from the plasma and urine matrix that can help determine precedent exposure to roasted coffee products. We review the published information on the coffee compound N-methylpyridinium in foods, coffee, and plasma/urine after coffee consumption, and evaluate the data in the context of the proposed food biomarker criteria “plausibility”, “time- and dose–response”, “robustness”, “reliability”, “stability”, “analytical performance”, and “reproducibility”. An additional data set is acquired to fill the gaps in the literature. In summary, we conclude that the abundance of NMP can serve as a reliable analytical tool to verify recent consumption of roasted coffee. The use of NMP appears limited to being qualitative, as NMP abundance in coffee and human biosamples is affected by several parameters, e.g., the roasting conditions and the volume and time of coffee consumed.
- Open Access
- 30 November 2023
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 71 (49) , 19516-19522
Consumption of Roasted Coffee Leads to Conjugated Metabolites of Atractyligenin in Human Plasma
Roasted coffee contains atractyligenin-2-O-β-d-glucoside and 3'-O-β-d-glucosyl-2'-O-isovaleryl-2-O-β-d-glucosylatractyligenin, which are ingested with the brew. Known metabolites are atractyligenin, atractyligenin-19-O-β-d-glucuronide (M1), 2β-hydroxy-15-oxoatractylan-4α-carboxy-19-O-β-d-glucuronide (M2), and 2β-hydroxy-15-oxoatractylan-4α-carboxylic acid-2-O-β-d-glucuronide (M3), but the appearance and pharmacokinetic properties are unknown. Therefore, first time-resolved quantitative data of atractyligenin glycosides and their metabolites in plasma samples from a pilot human intervention study (n = 10) were acquired. None of the compounds were found in the control samples and before coffee consumption (t = 0 h). After coffee, neither of the atractyligenin glycosides appeared in the plasma, but the aglycone atractyligenin and the conjugated metabolite M1 reached an estimated cmax of 41.9 ± 12.5 and 25.1 ± 4.9 nM, respectively, after 1 h. M2 and M3 were not quantifiable until their concentration enormously increased ≥4 h after coffee consumption, reaching an estimated cmax of 2.5 ± 1.9 and 55.0 ± 57.7 nM at t = 10 h. The data suggest that metabolites of atractyligenin could be exploited to indicate coffee consumption.
- 30 November 2023
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 71 (49) , 19516-19522
Open AccessConsumption of Roasted Coffee Leads to Conjugated Metabolites of Atractyligenin in Human Plasma
Roasted coffee contains atractyligenin-2-O-β-d-glucoside and 3'-O-β-d-glucosyl-2'-O-isovaleryl-2-O-β-d-glucosylatractyligenin, which are ingested with the brew. Known metabolites are atractyligenin, atractyligenin-19-O-β-d-glucuronide (M1), 2β-hydroxy-15-oxoatractylan-4α-carboxy-19-O-β-d-glucuronide (M2), and 2β-hydroxy-15-oxoatractylan-4α-carboxylic acid-2-O-β-d-glucuronide (M3), but the appearance and pharmacokinetic properties are unknown. Therefore, first time-resolved quantitative data of atractyligenin glycosides and their metabolites in plasma samples from a pilot human intervention study (n = 10) were acquired. None of the compounds were found in the control samples and before coffee consumption (t = 0 h). After coffee, neither of the atractyligenin glycosides appeared in the plasma, but the aglycone atractyligenin and the conjugated metabolite M1 reached an estimated cmax of 41.9 ± 12.5 and 25.1 ± 4.9 nM, respectively, after 1 h. M2 and M3 were not quantifiable until their concentration enormously increased ≥4 h after coffee consumption, reaching an estimated cmax of 2.5 ± 1.9 and 55.0 ± 57.7 nM at t = 10 h. The data suggest that metabolites of atractyligenin could be exploited to indicate coffee consumption.